logo

NVS

Novartis·NYSE
--
--(--)
--
--(--)
5.75 / 10
Netural

Novartis's fundamental score is 5.8/10, indicating average health. Strengths include a Days sales outstanding of 54 days (Group 1) and a Cost of sales ratio of 25.1% (Group 1), while challenges arise from an Income tax / Total profit ratio of 14.6% (Quartile 2). Interest coverage (15.3) and operating revenue growth (8.4% YoY) are moderate. Composite outlook: mixed, with no clear overvaluation or liquidity risk.

Fundamental(5.75)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.10
Score2/3
Weight16.62%
1M Return9.81%
Days sales outstanding
Value54.00
Score3/3
Weight1.77%
1M Return1.30%
Profit-MV
Value1.14
Score3/3
Weight20.34%
1M Return12.21%
PB-ROE
Value1.30
Score3/3
Weight24.30%
1M Return12.29%
Income tax / Total profit (%)
Value14.59
Score0/3
Weight-1.78%
1M Return-1.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.29
Score2/3
Weight-0.85%
1M Return-0.66%
Operating revenue (YoY growth rate %)
Value8.38
Score2/3
Weight0.73%
1M Return0.55%
Cost of sales ratio (%)
Value25.12
Score3/3
Weight1.03%
1M Return0.72%
Asset-MV
Value-0.50
Score2/3
Weight23.10%
1M Return11.67%
Cash-MV
Value0.66
Score2/3
Weight14.73%
1M Return7.70%
Is NVS undervalued or overvalued?
  • NVS scores 5.75/10 on fundamentals and holds a Fair valuation at present. Backed by its 30.84% ROE, 24.64% net margin, 21.34 P/E ratio, 6.41 P/B ratio, and 21.79% earnings growth, these metrics solidify its Netural investment rating.